BioCardia, Inc - רווח נקי למניה (EPS TTM) BCDA

The annual volatility of TTM net income per share allows for an assessment of the impact of CardioAMP patents and strict FDA oversight on capitalization. The clinical test outsourcing model minimizes costs, while experienced management strengthens shareholder confidence. The value of 63.70 captures this metric, helping to identify a hidden slowdown in the earnings growth rates of BioCardia, Inc. (BCDA) in a timely manner.

BioCardia, Inc. (BCDA) is currently focusing on clinical trials and has no commercial sales. Under these conditions, the trailing twelve months (TTM) net income per share growth rate reflects the dynamics of loss changes relative to the previous year. This metric calculates the percentage deviation of EPS over the last twelve months, measuring the efficiency of cost management. For BioCardia, Inc. (BCDA), increasing pipeline expenses directly impact the volatility of these values. Analysis of this chart allows for an assessment of the capital burn rate.